Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the largest dose of ON 01910.Na
(rigosertib sodium) that can be given safely as a 3-day continuous infusion once every 2
weeks (2-week cycle) in patients with advanced cancer.